New Delhi: Glenmark launched Nitric Oxide Nasal Spray (FabiSpray) in India in partnership with SaNOtize for treating adult patients infected with COVID-19.
It got manufacturing-marketing approval from India’s drug regulator the Drugs Controller General of India (DCGI) for Nitric Oxide Nasal Spray as part of the accelerated approval process.
“As a leading pharmaceutical player, it is important that we are an integral part of India’s fight against the COVID-19 pandemic. We are happy to receive regulatory approval for Nitric Oxide Nasal Spray (FabiSpray®) and launch it in partnership with SaNOtize. This reaffirms our commitment to providing yet another safe and effective antiviral treatment for COVID-19, and we are confident it will offer patients a much needed and timely therapy option,” Chief Commercial Officer, Glenmark Pharmaceuticals Ltd, Robert Crockart was quoted as saying by news agency ANI.
FabiSpray, Nitric Oxide Nasal Spray, is designed to kill the deadly virus in the upper airways. The spray has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2. NONS when sprayed over nasal mucosa acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs.
ALSO READ: India Logs 71,365 New COVID Cases; Positivity Rate Down To 4.5%
